科伦博泰 ADC 药物第三项适应症获批

Zhitong
2025.10.11 10:23

On October 11th, SKB BIO's antibody-drug conjugate Lukanasatuzumab (brand name: Jiatailai) received approval from the National Medical Products Administration for its third indication, to treat adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer with positive EGFR gene mutations that have progressed after treatment with epidermal growth factor receptor tyrosine kinase inhibitors

来源：Zhitong 本文版权归属原作者/机构所有。
当前内容仅代表作者观点，与本平台立场无关。内容仅供投资者参考，亦不构成任何投资建议。如对本平台提供的内容服务有任何疑问或建议，请联系我们。